Treatment Cessation in Chronic Myeloid Leukemia: Evidence and Uncertainties.

Hematol Oncol · 2025 · PMC12612388 · PMID 41225725

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although TFR probabilities were markedly lower in the e19a2 subgroup than in the e6a2/e8a2 subgroup with 12‐month rates of 66.7% versus 83.3% and 60‐month rates of 25.8% versus 83.3%, the difference did not reach statistical significance. 9.5.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.